Limitations 1 : 1 : Results should be interpreted with caution because of the retrospective pre-post design without a control or comparator arm and the relatively short follow-up (6 months) Hypoglycemia may have been underreported, as only the clinically significant events were likely to have been captured (eg, no SMBG or CGM data) EMR database analysis as a potential for selection bias that cannot be controlled, as well as EMR data-capture challenges (eg, coding errors, no dosing data) Patients were mainly from the Northwest and Southern US states and therefore may not be representative of the US national landscape Sanofi-sponsored study *Follow-up period 6 months included GLP-1 RA + Toujeo (N=271)
The underlying mechanisms may involve naringins capacity to modulate the activity of enzymes involved in cholesterol synthesis and catabolism, such as HMG-CoA reductase
On This Page Indications and Usage Dosage and Administration Dosage Forms and Strengths Contraindications Warnings and Precautions Adverse Reactions/Side Effects Drug Interactions Use In Specific Populations Overdosage Description Clinical Pharmacology Nonclinical Toxicology Clinical Studies How Supplied/Storage and Handling Storage and Handling Patient Counseling Information Highlights of Prescribing Information TOUJEO U-300 (insulin glargine) injection, for subcutaneous use Initial U.S
The severity of these injuries varies considerably
We ensure that what's on the label is exactly what's in the vial, giving your research a foundation of integrity